Primary pulmonary nuclear protein of the testis midline carcinoma: case report and systematic review with pooled analysis
Frontiers in Oncology · 09.01.2024 · 13
DOI: 10.3389/fonc.2023.1308432 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 09.01.2024. Verfasst von Dong Zhao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hebei Province, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
Nuclear protein of the testis (NUT) midline carcinoma (NMC) is a rare tumor, with particularly low incidence in the lungs, and a correspondingly poor prognosis. To determine the clinicopathological characteristics, outcomes, and prognostic factors of primary pulmonary NMC, a case was reported and a systematic review was performed. Twenty-nine records, including ours, involving 62 cases, were finally included. The median age at diagnosis was 29.5 years. At presentation, the most common symptoms at presentation were cough (47.50%) and chest/back pain (37.50%). In terms of diagnosis, 32.14% of NMC cases were identified through immunohistochemistry (IHC); However, a greater number of cases may be misdiagnosed initially, and ultimately, the diagnosis of NMC was confirmed through a combination of IHC and fluorescence in situ hybridization (FISH). Despite the clinical application of various chemotherapy-based treatments, the actual effectiveness remains unsatisfactory. Furthermore, Cox regression analysis of multiple factors identified male gender and concurrent presence of pleural effusion as indicators of shorter survival time in patients. These results emphasize the importance of increased diagnostic awareness among clinical and pathology practitioners concerning NMC. While there is currently no established standard for treating NMC, a treatment approach combining multiple methods shows promise for future research. Concurrently, clinical and foundational investigations addressing variables such as gender and the presence of pleural effusion may yield valuable insights into the diagnosis and treatment of NMC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China.
- Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Förderung
- Natural Science Foundation of Hebei Province
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Zhao, D., Cao, W., Zha, S., Wang, Y., Pan, Z., Zhang, J., & Hu, K. (2024). Primary pulmonary nuclear protein of the testis midline carcinoma: case report and systematic review with pooled analysis. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1308432
Vancouver
Zhao D, Cao W, Zha S, Wang Y, Pan Z, Zhang J, et al. Primary pulmonary nuclear protein of the testis midline carcinoma: case report and systematic review with pooled analysis. Frontiers in Oncology. 2024;13. doi:10.3389/fonc.2023.1308432
BibTeX
@article{Zhao2024,
author = {Zhao, Dong and Cao, Wei and Zha, Shiqian and Wang, Yixuan and Pan, Zhou and Zhang, Jingyi and Hu, Ke},
title = {Primary pulmonary nuclear protein of the testis midline carcinoma: case report and systematic review with pooled analysis},
journal = {Frontiers in Oncology},
year = {2024},
volume = {13},
doi = {10.3389/fonc.2023.1308432}
}
EUVIMED